Cancer nanomedicine meets immunotherapy: opportunities and challenges.

"Competing interests The authors declare no competing financial interests."

"This work was supported by the European Research Council (ERC: CoG-Meta-Targeting (864121), PoC-Picelles (813086), and CoG-ImmunoBioSynth (817938)), by the China Scholarship Council, by the European Union (European Fund for Regional Development: TAKTIRA (EFRE-0801767)), by the German Research Foundation (DFG: GRK/RTG 2375 Tumor-targeted Drug Delivery (project number: 331065168) and SFB 1066), by the Aachen Interdisciplinary Center for Clinical Research (IZKF; Project O3–2), and by the Federal Ministry of Education and Research (BMBF) and the Ministry of Culture and Science of the German State of North Rhine-Westphalia (MKW) under the Excellence Strategy of the Federal Government and the Länder (OPSF580). The work of RvdM is supported by the Netherlands Research Council (NOW: ZonMW Vici grant #016.176.622 to W.J.M. Mulder). HJY acknowledges financial support from the National Natural Science Foundation of China (51873228)."